Chalcogen Bonded Directly To Ring Carbon Of The Hetero Ring Patents (Class 514/460)
  • Patent number: 10307419
    Abstract: This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl -piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, that has excellent disintegration ability, storage stability and photostability. The tablet of the present invention comprising an uncoated tablet containing 7-[4-(4-benzo[b]thiophen-4 -yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, excipients such as lactose, corn starch, and microcrystalline cellulose; disintegrants such as low-substituted hydroxypropylcellulose, croscarmellose sodium, and sodium carboxymethyl starch; binders such as hydroxypropylcellulose; lubricants such as stearate; and further comprising a coating layer, containing hypromellose; talc; titanium oxide; colorant; and the like, the coating layer being applied to the surface of the uncoated tablet.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: June 4, 2019
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Yoshiharu Inoue
  • Patent number: 10231930
    Abstract: The present invention provides a method for producing a pharmaceutical composition which is a tablet and which contains tofogliflozin as an active ingredient. The method comprises mixing an additive and tofogliflozin to prepare a powder mixture and obtaining a tablet from the powder mixture by direct compression. The additive comprises at least one filler.
    Type: Grant
    Filed: December 26, 2014
    Date of Patent: March 19, 2019
    Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Kenta Wada, Tomoaki Hirayama, Kenichi Sakai, Shiho Yoshimura
  • Patent number: 10179157
    Abstract: The present invention discloses a slim and aqueous extract of Garcinia cambogia comprising (?)-hydroxycitric acid as dietary product for weight management. The present invention also discloses a process of preparation of aqueous extract wherein the Garcinia cambogia fruit rinds are subjected to cold circulation to retain the phytochemical components and the aqueous extract is adjusted to neutral pH and stabilized with triple mineral salt of calcium, magnesium and potassium and decolorized using activated carbon. The colorless, odorless aqueous extract obtained is subjected to qualitative and quantitative analysis to obtain pure concentrate, which is useful in food, beverage and pharmaceutical industries as dietary supplement. The concentrate equivalent to 1500 mg of (?)-hydroxycitric acid on dried basis is used for the consumption with the distilled water. The slim and aqueous extract concentrate of Garcinia cambogia is useful in treatment of overweight, obesity and hypercholesterolemia.
    Type: Grant
    Filed: February 15, 2016
    Date of Patent: January 15, 2019
    Inventors: Venkatachalam Hariharan, PradeepKumar Siddavvanahalli Virupakshappa, Kanchana Hariharan, Vinayaka Neechadi Puppadar, Paranjothi Kanni
  • Patent number: 10149830
    Abstract: The instant disclosure is related to lactone-containing compounds of formula (I), compositions thereof, and use thereof for treating proliferative disease or disorders. Also provided herein are methods of making, identifying, or characterizing the compounds, or compositions thereof.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: December 11, 2018
    Assignee: Cushing Academy
    Inventor: William R. Sponholtz, III
  • Patent number: 10040776
    Abstract: A compound of formula (I) is provided wherein R represents a linear or branched C5 alkyl group, as well as the use of such compounds in a fragrant and/or flavoring composition, or as a masking agent for odors and/or flavors.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: August 7, 2018
    Assignee: V. MANE FILS
    Inventors: Jean Mane, Caroline Plessis, Jean-Jacques Chanot
  • Patent number: 9914969
    Abstract: The present invention relates methods to increase the expression of fatty acid desaturases (FADS) and increase cellular and tissue levels of highly unsaturated fatty acids (HUFA) by modulating one or more of the FADS via the action of specific classes of drugs (e.g., statins and LXR agonists). The present invention also relates to methods of treating conditions (e.g., tumor and cancer) involving deficient function of FADS by administering statins and/or LXR agonists. The present invention further relates to methods of determining the need for statins or dietary LCPUFA in subjects.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: March 13, 2018
    Assignee: CORNELL UNIVERSITY
    Inventors: James Thomas Brenna, Holly Turner Reardon, Sesha Durga Kumar Kothapalli
  • Patent number: 9750759
    Abstract: A compound of general formula (I) wherein A, Y, R1, R2, R3, R4, R5, and R6 take various meaning or use in the treatment of cancer.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: September 5, 2017
    Assignee: Pharma Mar, S.A.
    Inventors: Alberto Rodriquez Vicente, Maria Garranzo Garcia-Ibarrola, Carmen Murcia Perez, Francisco Sanchez Sancho, Maria del Carmen Cuevas Marchante, Cristina Mateo Urbano, Isabel Digon Juarez
  • Patent number: 9630764
    Abstract: An oxygen-absorbing resin composition copolymerized polyolefin compound including a copolymerized polyolefin compound and a transition metal catalyst, wherein the copolymerized polyolefin compound is a copolymerized polyolefin compound including at least one of constitutional unit (a) selected from the group consisting of the constitutional units represented by the general formula (1), and at least one of the constitutional unit (b) having an indane ring, selected from the group consisting of the constitutional units represented by the general formulas (2) and (3).
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: April 25, 2017
    Assignee: MITSUBISHI GAS CHEMICAL COMPANY, INC.
    Inventors: Shinpei Iwamoto, Satoshi Okada, Shinichi Ikeda
  • Patent number: 9540307
    Abstract: The present invention relates to novel statin derivatives of omega-3 fatty acids, and their use in treating hypercholesterolemia, obesity, hypertriglyceridemia, cardiovascular diseases, and metabolic diseases, and Alzheimer's disease.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: January 10, 2017
    Assignee: JIVA PHARMA, INC.
    Inventor: Om P Goel
  • Patent number: 9434684
    Abstract: To provide a novel pesticide, especially a fungicide and a nematocide.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: September 6, 2016
    Assignee: Nissan Chemical Industries, Ltd.
    Inventors: Motoyoshi Iwasa, Keisuke Tsuji, Mitsutaka Tomizawa, Takeshi Mita, Hidehito Kuwahara, Miho Asahi, Hotaka Imanaka
  • Patent number: 9345671
    Abstract: The present invention provides a pharmaceutical composition for enhancement of adiponectin production, treatment or prevention of hypoadiponectinemia, and the like, comprising as an active ingredient an HMG-CoA reductase inhibitor.
    Type: Grant
    Filed: April 27, 2004
    Date of Patent: May 24, 2016
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Toshiyuki Takagi, Iichiro Shimomura, Yuji Matsuzawa, Tohru Funahashi
  • Patent number: 9321777
    Abstract: The disclosure relates to compounds of formula (I): wherein , A, W, X, and Ra are as defined in the disclosure, and salts thereof, and to pharmaceutical compositions comprising said compounds, to processes for preparing them, and to their use as medicaments, in particular as MET inhibitors.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: April 26, 2016
    Assignee: SANOFI
    Inventors: Eva Albert, Eric Bacque, Conception Nemecek, Antonio Ugolini, Sylvie Wentzler
  • Patent number: 9314029
    Abstract: Control or repellency of mosquitoes is accomplished by bringing the insects into contact with at least one of the compounds of the structure (I) wherein R is selected from —OH, ?O, —OC(O)R4, —OR6, —(OR6)2, wherein each R6 is independently selected from an alkyl group containing from 1 to 4 carbon atoms and R4 is a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; X is O or CH2, with the proviso that when X is O R can only be ?O; each Z is independently selected from (CH) and (CH2); y is a numeral selected from 1 and 2; R1 is selected from H or a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; R2 is selected from H and a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 15 carbon atoms; R3 is selected from the group consisting of H and a branched or straight chain, saturated o
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: April 19, 2016
    Assignee: Bedoukain Research, Inc.
    Inventor: Robert H. Bedoukian
  • Patent number: 9307783
    Abstract: Homeopathic water compositions are described, as well as beverage articles for making drinking water formulations with such compositions. One such beverage article includes a water bottle, and a dispensing cap adapted to be secured to the water bottle. The dispensing cap contains dried homeopathic composition-coated sucrose or sucrose/starch particles that are dispensable into water in the water bottle by user actuation of the dispensing cap, to constitute the homeopathic water formulation for consumption.
    Type: Grant
    Filed: July 29, 2012
    Date of Patent: April 12, 2016
    Assignee: ESSENTIALIFE HOMEOPATHICS
    Inventor: Ramin Stephan Bayani
  • Patent number: 9241914
    Abstract: The present invention concerns a method of enhancing milk production by a ruminant that includes providing a feed that contains sorbitol and at least one additional feed component, and orally feeding the feed to the ruminant, the ruminant ingesting about 100 grams, or less, of sorbitol per day.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: January 26, 2016
    Assignee: Land O'Lakes, Inc.
    Inventor: Cindie M. Luhman
  • Patent number: 9089612
    Abstract: This invention also provides a method to prevent, control, and treat a lipid metabolism disorder, a biliary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: July 28, 2015
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventor: Kunwar Shailubhai
  • Publication number: 20150148411
    Abstract: Provided are compositions and methods related to mutations in the Myh9 gene for aiding in diagnosing a subject as having an aggressive form of a cancer, for identifying an individual as a candidate for treatment with a nuclear export inhibitor, for determining whether tumor cells have defective p53 nuclear transportation, and for treating an individual diagnosed with an aggressive cancer.
    Type: Application
    Filed: November 25, 2014
    Publication date: May 28, 2015
    Inventors: Daniel Schramek, Elaine Fuchs
  • Publication number: 20150148410
    Abstract: An isolated peptidic fragment of apolipoprotein E comprises at least 3 contiguous amino acids, Including glycosylated threonine 194, threonine 289, serine 94, or serine 76 of SEQ ID NO.: 1, or any combination of those. An antibody capable of binding to the isolated peptidic fragment. A method of detecting a naturally-occurring circulating atherogenic low-density lipoprotein in a plasma sample from an individual, comprising qualitatively and/or quantitatively detecting in a low-density lipoprotein that binds to the antibody. A method of assessing an individual's risk of ischemic heart disease and/or atherosclerosis comprises quantifying in a plasma sample from the individual an amount of apolipoprotein E comprising glycosylated threonine 194, threonine 289, serine 94 or serine 76 of SEQ ID NO.: 1, or any combination of those.
    Type: Application
    Filed: September 10, 2012
    Publication date: May 28, 2015
    Applicant: Texas Heart Institute
    Inventors: Chu-Huang Chen, Liang-Yin Ke
  • Publication number: 20150148347
    Abstract: A compound of formula I, wherein the groups R1, R2, R3, X, m, and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Application
    Filed: November 25, 2014
    Publication date: May 28, 2015
    Inventors: Iain LINGARD, Dieter HAMPRECHT
  • Patent number: 9034921
    Abstract: A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: May 19, 2015
    Assignee: GREEN CROSS CORPORATION
    Inventors: Soongyu Choi, Kwang Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, So Ok Park, Hyunku Kang, Myung Eun Jung, Kinam Lee, Hyun Jung Kim, Jun Sung Lee, Min Woo Lee, Mi-Soon Kim, Dong Ho Hong, Misuk Kang
  • Publication number: 20150133540
    Abstract: Control or repellency of mosquitoes is accomplished by bringing the insects into contact with at least one of the compounds of the structure (I) wherein R is selected from —OH, ?O, —OC(O)R4, —OR6, —(OR6)2, wherein each R6 is independently selected from an alkyl group containing from 1 to 4 carbon atoms and R4 is a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; X is O or CH2, with the proviso that when X is O R can only be ?O; each Z is independently selected from (CH) and (CH2); y is a numeral selected from 1 and 2; R1 is selected from H or a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; R2 is selected from H and a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 15 carbon atoms; R3 is selected from the group consisting of H and a branched or straight chain, satur
    Type: Application
    Filed: April 30, 2013
    Publication date: May 14, 2015
    Inventor: Robert H. Bedoukian
  • Patent number: 9029413
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, and in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. Antiviral activity of enzyme inhibitors is demonstrated.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: May 12, 2015
    Assignee: The Trustees of Princeton University
    Inventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
  • Publication number: 20150119414
    Abstract: A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.
    Type: Application
    Filed: January 2, 2015
    Publication date: April 30, 2015
    Applicant: PIVOTAL THERAPEUTICS INC.
    Inventors: George JACKOWSKI, Rachelle MACSWEENEY, Nisar Ahmad SHAIKH, Jason YANTHA, Valerie B. SCHINI-KERTH
  • Publication number: 20150110871
    Abstract: The present invention relates to a gastric retentive tablet composition comprising: (1) coated particles essentially consisting of a drug and an amino methacrylate copolymer, (2) a methacrylic acid copolymer and (3) an excipient, wherein items 1, 2, and 3 are blended together, and then compressed into a gastric retentive tablet. Thus, the coated particles (item 1), a methacrylic acid copolymer and the excipient are evenly distributed in the tablet. The excipient is selected from a group consisting of a retarding agent, a binder, a filler, a chelating agent, a diluent, a disintegrant, a lubricant, a colorant, a solubilizing agent, or a mixture thereof. The coated particles (item 1) do not contain methacrylic acid polymer.
    Type: Application
    Filed: January 3, 2015
    Publication date: April 23, 2015
    Inventor: David Wong
  • Publication number: 20150104504
    Abstract: The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present substantially in the free acid form. Also provided are oral unit dosage forms of the disclosed pharmaceutical compositions and methods of treating blood lipid disorders using the compositions and oral unit dosage forms.
    Type: Application
    Filed: May 7, 2013
    Publication date: April 16, 2015
    Inventors: Bernardus Machielse, Timothy J. Maines, Michael H. Davidson, Bharat M. Mehta
  • Patent number: 9006468
    Abstract: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: April 14, 2015
    Assignee: Dow AgroSciences, LLC.
    Inventors: Gary D. Crouse, Thomas C. Sparks, CaSandra L. McLeod, David A. Demeter, Kristy Bryan, Annette V. Brown, William H. Dent, III, Denise P. Cudworth, Jaime S. Nugent, Ricky Hunter, Jack G. Samaritoni
  • Publication number: 20150094323
    Abstract: Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are provided.
    Type: Application
    Filed: December 8, 2014
    Publication date: April 2, 2015
    Inventor: Susanne Riel
  • Publication number: 20150094322
    Abstract: Pharmaceutical compositions of colchicine for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined or desired release profile. Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are also provided.
    Type: Application
    Filed: December 8, 2014
    Publication date: April 2, 2015
    Inventor: Susanne Riel
  • Publication number: 20150080463
    Abstract: Methods are provided for diagnosing the risk of a cardiovascular event in a patient. In some embodiments, the method includes measuring the level of proprotein convertase subtilisin kexin type 9 (PCSK9) in a sample obtained from a patient and comparing the measured level of PCSK9 to a control. Also provided are methods of selecting a therapy for a patient prior to administration of the therapy. In some embodiments, the method includes measuring a PCSK9 blood concentration in a sample from a patient to determine the presence or absence of a PCSK9 blood concentration indicative of responsiveness to an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Further provided are methods for assessing the efficacy of a therapy being administered to a patient. In certain embodiments, the method includes detecting a change in a PCSK9 blood concentration in a sample from a patient, wherein a change in detected levels is indicative of whether the therapy is efficacious.
    Type: Application
    Filed: March 16, 2011
    Publication date: March 19, 2015
    Applicant: BG MEDICINE, INC.
    Inventor: Pieter Muntendam
  • Publication number: 20150065567
    Abstract: Administration of certain 1-phenylalkanecarboxylic acid derivatives is useful for treating, preventing and/or reducing the risk of developing Alzheimer's Disease and multiple sclerosis.
    Type: Application
    Filed: August 15, 2014
    Publication date: March 5, 2015
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Bruno Imbimbo, Marina Pizzi, Daniel Chain
  • Patent number: 8969397
    Abstract: Disclosed herein are systems and methods for contributing to the local treatment of pain. More specifically, the disclosed systems and methods contribute to the local treatment pain by inhibiting the NF?B family of transcription factors.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: March 3, 2015
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Eric N. Burright, Lisa L. Shafer, Bill McKay, John Zanella
  • Patent number: 8969390
    Abstract: The invention relates to liquid compositions which contain a) from 40 to 99.9% by weight of sorbitan monocaprylate and b) from 0.1 to 60% by weight of one or more antimicrobial substances selected from the group consisting of the components b1) to b5): b1) specific organic acids and the salts thereof, b2) specific formaldehyde donors, b3) specific isothiazolinones, b4) specific paraben esters and the salts thereof, and b5) specific pyridones and the salts thereof. The liquid compositions are suitable for the production of cosmetic, dermatological or pharmaceutical products.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: March 3, 2015
    Assignee: Clariant Finance (BVI) Limited
    Inventors: Peter Klug, Sonja Gehm, Guiseppina Kluth, Franz-Xaver Scherl, Maurice Frederic Pilz
  • Publication number: 20150051235
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.
    Type: Application
    Filed: October 21, 2014
    Publication date: February 19, 2015
    Applicant: Infirst Healthcare Limited
    Inventors: Robin Mark Bannister, John Brew, Suzanne Jane Dilly, Gregory Alan Stoloff, Wilson Caparros-Wanderley
  • Publication number: 20150051256
    Abstract: The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 19, 2015
    Applicant: Takeda Pharmaceutical Company Limited
    Inventor: Naomi Kitamoto
  • Publication number: 20150051276
    Abstract: Compounds are used as agents that deter feeding of crops by agricultural pests such as hemiptera, lepidoptera and coleoptera, including, but not limited to, stink bugs, codling moth larvae and granary weevils.
    Type: Application
    Filed: April 30, 2013
    Publication date: February 19, 2015
    Inventor: Robert H. Bedoukian
  • Publication number: 20150045424
    Abstract: It is described the use of L-carnitine and/or an alkanoyl L-carnitine, or a pharmaceutically acceptable salt thereof, in combination with a statin, for the preparation of a medicament for the treatment of type 2 diabetes.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 12, 2015
    Inventors: Franco GAETANI, Ashraf VIRMANI
  • Patent number: 8946457
    Abstract: Flavone derivatives, preparative method of the derivatives and use thereof as medicaments for treating diabetes. The structure of the derivatives is presented by formula 1: In the structure, R1 and R2, which are identical or not, represent hydrogen atom, halogen, cyano, hydroxyl, trifluoromethyl, thio-methyl, benzyloxy. C1-C8 linear chain or branch chain alkyl, C1-C8 linear chain or branch chain alkoxy. The pharmacological test indicates that the flavone derivatives can significantly increase the glucose consumption of Hep-G2 cell with insulin resistance activity, promote translocation of glucose transporter 4 of skeletal muscle cells (L6GLUT4myc) at different level, and significantly increase glucose intake and utilization by cells.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: February 3, 2015
    Assignee: Tianjin Medical University
    Inventors: Hongquan Duan, Nan Qin, Wenyan Niu, Meina Jin, Lihuan Shi, Ying Chen
  • Patent number: 8940911
    Abstract: A library of unnatural squarylated homoserine lactones (SHLs) and squarylated lactones that bear potential to modulate biofilm formation in Gram negative bacteria. At low concentrations (˜200 ?M), these small molecules inhibit biofilm formation of E. coli. Moreover, these compounds are not toxic up to 300 ?M and do not significantly attenuate E. coli growth. The SHLs have potential to disperse established biofilm and demonstrate an enhanced reduction (˜50%) of the maximum biofilm thickness by use of SHLs during biofilm growth.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: January 27, 2015
    Assignee: Syracuse University
    Inventors: Yan-Yeung Luk, Sri Kamesh Narasimhan, Eric Falcone
  • Publication number: 20150025134
    Abstract: The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 22, 2015
    Inventor: Thomas Najarian
  • Publication number: 20150025069
    Abstract: This invention is directed to analogs of 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA) and their use in the treatment of dermatological disorders or conditions characterized by sebaceous gland hyperactivity, such as acne and oily skin, and other dermatological disorders and conditions. This invention is also directed to pharmaceutical compositions comprising analogs of TOFA and a pharmaceutically acceptable excipient for dermatological or oral administration.
    Type: Application
    Filed: October 3, 2014
    Publication date: January 22, 2015
    Inventors: Timothy Scott Daynard, Geoffrey C. Winters, David W.C. Hunt
  • Publication number: 20150023868
    Abstract: The present invention is directed to HIF inhibitors and methods of preventing cell proliferation, reducing inflammation, and treating an angiogenic disease or disorders.
    Type: Application
    Filed: February 21, 2014
    Publication date: January 22, 2015
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Othon Iliopoulos, Michael Zimmer
  • Publication number: 20150018378
    Abstract: The present invention relates methods to increase the expression of fatty acid desaturases (FADS) and increase cellular and tissue levels of highly unsaturated fatty acids (HUFA) by modulating one or more of the FADS via the action of specific classes of drugs (e.g., statins and LXR agonists). The present invention also relates to methods of treating conditions (e.g., tumor and cancer) involving deficient function of FADS by administering statins and/or LXR agonists. The present invention further relates to methods of determining the need for statins or dietary LCPUFA in subjects.
    Type: Application
    Filed: January 28, 2013
    Publication date: January 15, 2015
    Inventors: James Thomas Brenna, Holly Turner Reardon, Sesha Durga Kumar Kothapalli
  • Publication number: 20150011525
    Abstract: A stable ternary solid dispersion composition with enhanced physical stability and/or bioavailability comprising: (a) about 1% wt. to about 50% wt. of one or more poorly soluble active pharmaceutical ingredient (API) which belongs to Biopharmaceutics Classification System (BCS) class II and/or IV; (b) about 11% wt. to about 50% wt. of at least one water-soluble polymer; and (c) about 20% wt. to about 99% wt. of crosslinked polyvinylpyrrolidone (crospovidone, a water-insoluble polymer). The solid dispersion is capable of inhibiting crystallization of API in solid state and/or aqueous gastrointestinal tract (GIT) medium. Also disclosed is a method of preparation of such solid dispersion composition by fusion or solvent or fusion-solvent method.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 8, 2015
    Applicant: ISP Investments Inc.
    Inventors: Yunxia Bi, Mohammed Abdul Rahman, James David Lester
  • Publication number: 20150010469
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer, stereoisomer or deuterated analogue thereof, wherein X, R, R1, R2, R3, R4, M1, M2, L1, L2, J1, J2, a1, a2, b1 and b2 are as defined herein, are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
    Type: Application
    Filed: July 3, 2014
    Publication date: January 8, 2015
    Applicants: British Columbia Cancer Agency Branch, University of British Columbia
    Inventors: Raymond John Andersen, Javier Garcia Fernandez, Marianne Dorothy Sadar
  • Patent number: 8927599
    Abstract: The use of statins as antiepileptic, anticonvulsant, neuroprotector and antioxidant compounds, potentially useful for the prevention and/or treatment of epilepsy, epileptic seizures, convulsions, neurodegenerative diseases, or diseases associated with undesired oxidation, is described.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: January 6, 2015
    Assignee: Neuron Biopharma, S.A.
    Inventors: Javier Santos Burgos Muñoz, Carlos Ramirez Moreno, Javier Velasco Alvarez
  • Publication number: 20150005351
    Abstract: Methods are disclosed for determining a patient's risk for developing Alzheimer's disease and preventing or treating Alzheimer's disease. Kits for assessing a patient's risk of developing Alzheimer's are also provided.
    Type: Application
    Filed: June 26, 2014
    Publication date: January 1, 2015
    Inventors: Salvador Soriano, Michael Castello
  • Patent number: 8921320
    Abstract: A targeted osmotic lysis (TOL) of tumor cells that over-express voltage-gated sodium channels (VGSCs) has been developed that uses a combined therapy of a drug that blocks sodium, potassium-adenosine triphosphatase (Na+, K+-ATPase) that is then followed by an activation of VGSCs, for example, by electrical or pharmacological stimulation. Activation of VGSCs conducts sodium into the cancer cells in much greater amounts than non-cancer cells. Water follows this sodium gradient into the cancer cells, causing swelling and lysis. Because non-cancerous cells do not over-express VGSCs, less sodium and less water will enter the cells, and the non-cancerous cells will not lyse. This method is applicable to all cells that over-express VGSCs, including, but not limited to, highly invasive breast cancer, prostate cancer, small cell lung cancer, non-small cell lung carcinoma, lymphoma, mesothelioma, neuroblastoma, and cervical cancer.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: December 30, 2014
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Dennis J. Paul, Harry J. Gould
  • Publication number: 20140374516
    Abstract: Disclosed is a process for the preparation of drug/carrier inclusion composites which involves co-grinding the mixture of drug and carrier powders in a fluid-jet mill, in particular one using air or nitrogen as the fluid, which is suitably modified to allow mechanical fusion of the powders.
    Type: Application
    Filed: January 25, 2013
    Publication date: December 25, 2014
    Applicant: MICRO-MACINAZIONE S.A.
    Inventors: Fabio Carli, Piero Iamartino, Milko Leone
  • Patent number: 8916717
    Abstract: The invention relates to dioxaspiroketal derivatives of formula (I): wherein R, is selected from the group consisting of H, straight or branched chain C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, cycloalkyl, heterocyclyl, phenyl, optionally para-, meta- or ortho-substituted with 0 to 3 substituent selected from halogen, —CN, —NH2, —OH, —NO2, COOR2, wherein R2 is selected from H and C1-C6 alkyl, n is 1 or 2, X is O or S, R1 is selected from H, OH, halogen, C1-C6 alkyl, C1-C6 alkoxy, COOR3, wherein R3 is selected from H and C1-C6 alkyl, or physiologically acceptable salts thereof, process for preparation thereof, their uses in medical field, in particular as anti-tumor medicaments.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: December 23, 2014
    Assignee: Consiglio Nazionale Delle Ricerche
    Inventors: Antonella DeMico, Andrea Cottarelli, Mariapia Fuggetta, Giulia Lanzilli, Maria Tricarico
  • Publication number: 20140370060
    Abstract: The present invention relates to a method of stabilising a tear film in an individual having an ocular surface inflammatory disorder by providing a compound to an ocular surface of the individual to reduce the synthesis of a cholesterol by a meibum-producing tissue.
    Type: Application
    Filed: February 1, 2013
    Publication date: December 18, 2014
    Inventors: Kenneth Gek-Jin Ooi, Stephanie Louise Watson